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Abstract
Background: Canine atopic dermatitis (CAD) is a chronic inflammatory skin disease triggered by allergic reactions
involving IgE antibodies directed towards environmental allergens. We previously identified a ~1.5 Mb locus on
canine chromosome 27 associated with CAD in German shepherd dogs (GSDs). Fine-mapping indicated association
closest to the PKP2 gene encoding plakophilin 2.
Results: Additional genotyping and association analyses in GSDs combined with control dogs from five breeds
with low-risk for CAD revealed the top SNP 27:19,086,778 (p = 1.4 × 10−7) and a rare ~48 kb risk haplotype
overlapping the PKP2 gene and shared only with other high-risk CAD breeds. We selected altogether nine SNPs
(four top-associated in GSDs and five within the ~48 kb risk haplotype) that spanned ~280 kb forming one risk
haplotype carried by 35 % of the GSD cases and 10 % of the GSD controls (OR = 5.1, p = 5.9 × 10−5), and another
haplotype present in 85 % of the GSD cases and 98 % of the GSD controls and conferring a protective effect
against CAD in GSDs (OR = 0.14, p = 0.0032). Eight of these SNPs were analyzed for transcriptional regulation using
reporter assays where all tested regions exerted regulatory effects on transcription in epithelial and/or immune cell
lines, and seven SNPs showed allelic differences. The DNA fragment with the top-associated SNP 27:19,086,778
displayed the highest activity in keratinocytes with 11-fold induction of transcription by the risk allele versus 8-fold
by the control allele (pdifference = 0.003), and also mapped close (~3 kb) to an ENCODE skin-specific enhancer region.
Conclusions: Our experiments indicate that multiple CAD-associated genetic variants located in cell type-specific
enhancers are involved in gene regulation in different cells and tissues. No single causative variant alone, but rather
multiple variants combined in a risk haplotype likely contribute to an altered expression of the PKP2 gene, and
possibly nearby genes, in immune and epithelial cells, and predispose GSDs to CAD.
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Background
Canine atopic dermatitis (CAD) is defined as an inflam-
matory and pruritic allergic skin disease with a genetic
predisposition and where the development is influenced
by environmental factors [1, 2]. The symptoms of CAD
include eczematous skin predominantly in the flex and
friction areas of the body [3], very similar to atopic
dermatitis (AD) in humans [4, 5]. The immune response
is primarily due to immunoglobulin E (IgE) antibodies
recognizing harmless environmental allergens, resulting
in a degranulation of active mediators, such as hista-
mine, by mast cells and eosinophils. The overall preva-
lence of CAD in dogs has been difficult to estimate, but
reports typically range from 3–15 % [6, 7]. Genetic fac-
tors are likely to play a substantial role in CAD as it is
highly overrepresented in certain high-risk (HRCAD)
dog breeds including Boxer, Bull terrier, West Highland
white terrier (WHWT), German shepherd dog (GSD),
Labrador retriever (LR) [8–11], and Golden retriever
(GR) [10, 12]. Face, ears (otitis externa), paws, extrem-
ities, ventrum, and flex-zones are typically affected by
pruritus and erythema [3]. The affected body-regions
seem to differ between breeds. GSDs for example are
typically affected by otitis externa and eczema of the
belly/groin, whereas Boxers are predisposed to facial
area symptoms [10].
Several genetic risk factors have been suggested to
contribute to the development of AD in humans [13]
and dogs [14]. Genes reported in human AD predomin-
antly fall into two main pathophysiological groups: i)
immune-mediated pathways and ii) skin barrier func-
tions [13]. The most striking findings are mutations in
the filaggrin gene (FLG) associated with AD [15].
Filaggrin represents one of the proteins that are essential
for the cornified envelope of the epidermis [16]. FLG
mutations lead to an impaired skin barrier, which
enhances allergen penetrance and subsequently cutane-
ous inflammation driven by type 2 T helper (Th2) cells,
and to some extent explain AD predisposition in
humans. Interestingly, an altered FLG mRNA and
protein expression has been detected in skin of atopic
dogs when compared to skin from healthy control dogs
[17]. Moreover, a mutation in the plakophilin 1 gene
(PKP1) resulting in PKP1 protein deficiency in the skin
causes ectodermal dysplasia-skin fragility syndrome in
Chesapeake Bay retriever dogs [18]. The same skin fra-
gility disease caused by PKP1 protein loss has been
detected also in human [19]. Thus, we anticipate that
genetic risk factors identified for CAD may be of
importance for human skin diseases such as AD.
In our previous study [20], we identified a ~1.5 Mb risk
haplotype on canine chromosome 27 (CFA27) associated
with CAD in GSDs (GWAS top SNP 27:19,140,837 on
CanFam2.0; praw = 3.1 × 10
−7, pgenome = 0.03). Targeted re-
sequencing and further genotyping in GSDs suggested the
strongest association in a ~209 kb region harboring the
plakophilin 2 gene (PKP2), which was subsequently sug-
gested as the top candidate gene [20]. PKP2 proteins
recruit desmoplakin to cell-cell contacts and are crucial
for a proper desmosome assembly [21]. Desmosomes are
intercellular mechanical junctions that contribute to
strength and integrity in tissues such as the myocardium
and epidermis that exhibit mechanical stress [22]. Other
functions of plakophilins include involvement in multiple
signaling and metabolic processes, and also in transcrip-
tional activity (reviewed in [23]). For example, PKP2 binds
to β-catenin in the cytoplasm and overexpression of PKP2
has been suggested to reduce the pool of β-catenin avail-
able for E-cadherin binding, which may thereby affect cell
adhesion [24]. Moreover, PKP2 forms complexes with
RNA polymerase III subunits and is generally present in
the nuclei of many cell types. Interestingly, in the top
layers of skin epithelia PKP2 is excluded from the desmo-
somes and instead accumulated in the nuclei of the kerati-
nocytes [24]. In addition to PKP2, the genes YARS2
(tyrosyl-tRNA synthetase), DNM1L (Dynamin 1-like), and
FGD4 (FYVE, RhoGEF and PH domain containing 4) may
potentially be involved in CAD development, due to their
location close (~30-150 kb) to the associated locus.
Here, we aimed at scrutinizing the PKP2 risk locus,
pinpointing candidate variants and investigating their
functionality. We performed an across-breed analysis
that defined one top-associated SNP and a rare 48 kb
risk haplotype in GSDs overlapping with regions of high
regulatory potential within the PKP2 gene. Eight candi-
date SNPs were included in functional evaluation and
displayed variable regulatory potential and allelic differ-
ences dependent on cell type.
Results
Genotyping of SNPs located within the PKP2 locus
We genotyped in total 381 dogs including GSDs and
various other breeds with either high or low risk for
CAD (HRCAD or LRCAD breeds; Methods) for 120
SNPs spanning a region of ~1 Mb (see Additional file 1:
Table S1 for both CanFam2 and CanFam3.1 SNP posi-
tions). The SNPs were in LD with the top-associated
GWAS SNPs [20] and selected based on multiple cri-
teria. SNPs that were not present in previously published
whole genome sequence data from LRCAD breed pools
[25] were regarded as potentially functionally important
as well as SNPs located in regulatory regions according
to the human UCSC browser. Finally, SNPs were se-
lected to cover the region sufficiently and the previous
top SNPs were included as references. For details see
Methods. The majority of the genotyped SNPs (NSNPs =
102) were located in a 340 kb region within the PKP2
locus, including the top-associated region (~209 kb)
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defined by previous fine-mapping [20]. After quality con-
trol, 370 dogs and 104 SNPs (out of which seven were in-
cluded in previous fine-mapping) remained (Table 1 and
Additional file 1: Table S1 and Additional file 2: Table S2).
Two top-associated SNPs from the association analysis in
GSDs
In a first attempt to narrow down the CAD-associated
region in GSD, we performed association analysis in
GSDs only (Ncases = 91 and Ncontrols = 83, same as in
[20]) resulting in one additional top SNP 27:19,086,778
with the same p-value (p = 2.7 × 10−6) as the top GWAS
SNP 27:19,140,837 [20]. These two SNPs were in very
high linkage disequilibrium (LD; r2 ≥ 0.95) with eight
other associated SNPs defining a ~209 kb region: from
SNP 27:18,934,038 to SNP 27:19,143,309 (Fig. 1a and
Additional file 3: Table S3).
A ~48 kb risk haplotype in GSDs defined using additional
breeds
While we were unable to narrow down the associated
region using GSDs only, we hypothesized that other
breeds could be used for breaking down the LD and
thereby narrow down the CAD-associated region in
GSDs. We therefore performed an association analysis
in GSDs together with 5–10 control dogs from each of
five different LRCAD breeds: Elkhound, Hovawart, Giant
Schnauzer, Smalands hound, and Irish Wolfhound. CAD
rarely affects these breeds and the sampled dogs were
assumed to be CAD controls. This analysis was subse-
quently performed by comparing GSD CAD cases to
CAD controls of GSD and five LRCAD breeds, and re-
sulted in the same top SNP 27: 19,086,778 as in the
GSD association analysis with a highly significant p-
value (p = 1.4 × 10−7). The second most associated SNP
27:19,135,677 (p = 1.7 × 10−6) was in very strong LD
(r2 ≥ 0.95, in the studied population) with six moderately
associated SNPs (p = 3.3 × 10−6–4.1 × 10−5) defining a
~48 kb region covering half of the sixth intron to 19 kb
downstream of PKP2 (Fig. 1b and Additional file 4: Table
S4). The risk alleles at these seven SNP positions formed
a risk haplotype present in 36 % of the GSD cases and
10 % of the GSD controls and conferred an OR for CAD
of 5.3 (95 % confidence interval, CI: 2.3–12.4, p = 3.1 ×
10−5) in GSDs. For comparison, the more common risk
allele at the top GWAS SNP 27:19,140,837 was present
in 64 % of the cases and 31 % of the controls conferring
with an OR of 3.9 (95 % CI: 2.1–7.2, Fisher’s exact prob-
ability test two-tailed: p = 2.1 × 10−5) for CAD. Next, we
studied the genotypes of the dogs of HRCAD breeds
listed in Table 1 and detected that the 48 kb risk haplo-
type was present at a high frequency (88 %) in LRs (in
16 out of 21 cases and in 12 out of 14 controls) and at a
low frequency (4 %) in GRs (in one out of 10 cases and
in none of the 15 controls). Half of the risk haplotype,
consisting of five SNPs spanning ~21 kb from intron 6
to 10 of PKP2, was present in 58 % of the WHWTs: in
12 out of 18 cases (~42 kb in one WHWT case) and 7
out of 15 controls (Fig. 1c, Additional file 2: Table S2
and Additional file 5: Table S5). Due to the low sample
numbers of these breeds, no conclusion could be drawn
about association to CAD. The risk haplotype was not
detected (nor part of it) in the other HRCAD breeds:
Boxers (N = 39), Bull terriers (N = 19), Irish soft-coated
wheaten terrier (N = 2), Jack Russell terrier (N = 1) or the
dog of mixed breeds, or in any of the LRCAD breeds. Of
note, the region including the ~48 kb shared haplotype
and SNP 27:19,086,778 contains prominent H3K4Me1
enhancer-associated histone modification marks (based
on ENCODE data) detected in normal human epidermal
keratinocytes (NHEK) and human mammary epithelial
cells (HMEC) (Fig. 1d).
SNP 27:19,093,355 tags the ~48 kb risk haplotype
To evaluate all possible regulatory variants located in
the ~48 kb risk haplotype, we considered the SNPs from
the fine-mapping plus 107 additional SNPs observed in
five previously re-sequenced GSDs [20]. Nine SNPs, in
LD with the top two associated GWAS SNPs, were not
detected in any of the LRCAD breeds, human, or other
species, thus suggesting functional importance (see Ma-
terials and Methods and Additional file 6: Table S6). The
best transcription factor (TF) binding site prediction
(using TRAP [26, 27]) was detected for SNP 27:19,093,355
with the allele-specific binding of nine members of the
Table 1 Dogs included in genotyping of 120 SNPs
Breed CAD cases CAD controls
German shepherda 91 83
Labrador retrievera 21 14
Golden retrievera 10 15
West Highland white terriera 18 15
Boxera 22 17
Bull terriera 12 7
Irish soft coated wheaten terriera 2 0
Jack Russell terriera 1 0
Wachtelhunda 1 0
Elkhoundb 0 5
Hovawartb 0 8
Giant Schnauzerb 0 10
Smalands houndb 0 9
Irish wolfhoundb 0 8
Mixed 0 1
Total number of dogs after quality controls 178 192
aHRCAD breeds, bLRCAD breeds
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GATA family of TFs with the most significant score for
binding of GATA6 (p = 4.5 × 10−4) to the risk allele com-
pared to the wild-type (p = 0.84; absolute difference log(p)
= −3.3; Additional file 7: Table S7). SNP 27:19,093,355 was
among the SNPs defining the 48 kb and the shorter 21 kb
risk haplotype. We then genotyped additional dogs of the
HRCAD breeds (GSDs, LRs, GRs, and WHWTs) for the
SNP 27:19,093,355 and after quality controls, considering
genotyping success and CAD status, the datasets were
combined with the fine-map datasets. In LRs (Ncases = 130,
Ncontrols = 110) and WHWTs (Ncases = 44, Ncontrols = 18)
the frequencies of the risk allele were high in both cases
and controls where 79 % of the LR cases and 82 % of
the LR controls, and 55 % of the WHWT cases and
56 % of the WHWT controls carried the risk allele.
In GRs (Ncases = 165, Ncontrols = 179) the risk allele
was present in 3 % of the cases and in none of the
controls. In the separate set of GSDs (Ncases = 73,
Ncontrols =140), the risk allele was present in 29 % of
the cases and 13 % of the controls conferring an OR
of 2.7 (95 % CI: 1.3–5.6, p = 0.0054) for CAD. Since
the risk allele of SNP 27:19,093,355 was unique to
HRCAD breeds in our fine-map dataset, we evaluated
its presence in other breeds by genotyping various
number of dogs representing in total 43 different
breeds (Additional file 8: Table S8). In addition to the
GSD, GR, LR and WHWT, the risk allele was also
present in the eight breeds: Bearded collie, Border
collie, English springer spaniel, Finnish Lapphund,
Giant Schnauzer, Nova Scotia duck tolling retriever,
Poodle, and Welsh springer spaniel (Additional file 9:
Table S9 and Additional file 10: Table S10).
Nine SNPs define one major risk and one major
protective haplotype in GSDs
For further validation, we selected the top SNPs from
both GWAS [20] and fine-mapping analyses (Fig. 1c,
Table 2 and Additional file 11: Table S11). These in total
nine SNPs covered a ~280 kb region and we identified
21 different haplotypes (Additional file 12: Table S12)
across all breeds listed in Table 1 (Additional file 2:
Table S2). The most common haplotype in GSD (haplo-
type 5) consisted of the control alleles (i.e. alleles more
frequent in control GSDs compared to case GSDs) at all
nine SNP loci and was present in 11 breeds, i.e. all
breeds except LR, WHWT, and Jack Russell terrier. In
GSDs, haplotype 5 was present in 98 % of the controls
and 85 % of the cases, and conferred a protective effect
on CAD (OR = 0.14 with 95 % CI: 0.03–0.6; p = 0.0032).
The risk alleles at all SNP loci defined another haplotype
(haplotype 20) detected only in the HRCAD breeds
GSD, LR, and GR. In GSDs, 35 % of the cases carried
haplotype 20 compared to 10 % of the controls. Thus,
this haplotype conferred a high risk for CAD (OR = 5.1
with 95 % CI: 2.2–11.9, p = 5.9 × 10−5) in GSDs
(Table 2).
Eight candidate SNPs located in cell type-specific
enhancers
We used luciferase reporter assays to further evaluate
the regulatory potential of the selected candidate
variants. The SNP 27:19,124,996 was excluded due to
the complicated repetitive region surrounding this SNP,
leaving us with eight candidate variants for functional
evaluation. Transient transfections followed by luciferase
assays were performed using fragments ranging in size
between 164 bp and 517 bp including the associated
SNPs (Materials and Methods; Additional file 13: Table
S13) in four different cell lines representing epithelial
and immune cells that might be relevant to the disease:
Madin-Darby canine epithelial cell line from Cocker
spaniel (MDCK), human keratinocyte cell line (HaCaT),
human T cell line (Jurkat), and human erythromyelo-
blastoid leukemia cell line (K562). We found that all
eight regions have regulatory potential by either enhan-
cing or inhibiting the activity of the luciferase gene, in at
least one of the tested cell lines. Significant allele-
specific differences on expression varied greatly between
(See figure on previous page.)
Fig. 1 Association analyses in GSDs and LRCAD breeds revealed candidate variants located in tissue-specific enhancers. Association analyses
including 104 fine-map SNPs located within the PKP2 locus on CFA27 were performed separately in GSDs and in GSDs combined with LRCAD
breeds. a. The GSD association analysis defined a ~209 kb associated region by associated SNPs displaying high linkage (r2 > 0.95) with the two
top SNPs 27:19,086,778 (blue and index SNP) and 27:19,140,837 (index SNP). b. The combined association analysis including LRCAD breeds
revealed the highly significant top SNP 27:19,086,778 (blue), and SNP 27: 19,135,677 (index SNP) in high LD (r2 > 0.95) with seven SNPs forming a
~48 kb risk haplotype. c. The ~48 kb risk haplotype (pink bar) stretched from PKP2 intron 6 to the downstream region of the gene and was
present in GSD, LR, and GR. A 21 kb risk haplotype (red bar) stretching from intron 6–10 was shared with WHWT. Asterisks and SNP positions mark
the nine SNPs included in further analyses: purple and light blue SNPs were top SNPs in the GSD association and green SNPs were part of the
~48 kb risk haplotype. d. Positions of the SNPs in the human UCSC browser, where SNP 27:19,112,169 and 27:19,135,677 were not mapped from
dog to human due to loss of conservation around the SNPs, and SNP 27: 27:19,124,996 (light blue) was not included in the luciferase experiments
due to its location in a repetitive region. e. When matching the ~48 kb haplotype plus the SNP 27:19,086,778, to human ENCODE data, H3K4Me1
enhancer-associated histone modification marks were detected in normal human epidermal keratinocytes (NHEK) and human mammary epithelial
cells (HMEC) (purple and green, respectively). f. The regulatory potential within the region is indicated by the tracks from the human UCSC
browser (hg18): Transcription Factor ChIPSeq, HMR Conserved transcription factor binding sites, ESPERR and Regulatory Potential and conservation
scores by PhyloP across placental mammals (https://genome.ucsc.edu/cgi-bin/hgGateway?db=hg18)
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Table 2 Nine SNPs selected for functional evaluation
SNP SNP 27:18,
861,228
SNP 27:19,
086,778
SNP 27:19,
093,355
SNP 27:19,
096,199
SNP 27:19,
112,169
SNP 27:19,
114,170
SNP 27:19,
124,996
SNP 27:19,
135,677
SNP 27:19,
140,837
Haplotype
ID
GSD cases
(%) a
GSD controls
(%) a
p-valueb OR
Control alleles C C C T A C T G T 5 84.6 97.6 0.0032 0.14
(95 CI: 0.03–0.6)
Risk alleles A T T G G G A A G 20 35.2 9.6 5.9×10
−5
5.1
(95 CI: 2.2–11.9)
Association p-value
in GSD
1.3×10−5 2.7×10−6 7.1×10−5 2.8×10−5 1.9×10−5 1.9×10−5 3.8×10−6 1.0×10−5 2.7×10−6
Rank in association
analyses:
GWAS 2 na na na na na na na 1
GSD
fine-map
16 1 37 26 21 20 3 12 1
GSD + LRCAD breeds 64 1 9 4 2 3 14 1 15
Haplotype 5 was present in GSD, Boxer, Smalands hound, Golden retriever, Bull terrier, Elkhound, Hovawart, Giant Schnauzer, Irish wolfhound, Irish soft-coated wheaten terrier, and Wachtelhund
Haplotype 20 was present in GSD, Labrador and Golden retriever
a Dogs either heterozygous or homozygous for the allele in %
b Fisher’s Exact probability test, two-tailed
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cell types and were detected for seven out of the eight
SNPs (Fig. 2). An overview of the complete workflow
starting from previous findings, through the current
study design and the major results from both association
analyses and functional analysis is presented in Fig. 3.
The allelic differences on expression were more
commonly observed in cells of hematopoietic origin
(K562 and Jurkat), while the most profound effect on
gene expression was detected for the SNP 27:19,086,778
in the epithelial cells (HaCaT and MDCK). Significant
repressive effects by the risk allele compared to the con-
trol were detected for two regions (SNP 27:19,096,199
(See figure on previous page.)
Fig. 2 Regulatory potential and allelic differences of candidate regions. Luciferase reporter assays for each of the eight evaluated SNPs
(SNP 27:18,861,228, SNP 27:19,086,778, SNP 27:19,093,355, SNP 27:19,096,199, SNP 27:19,112,169, SNP 27:19,114,170, SNP 27:19,135,677, and
SNP 27:19,140,837) were performed in four different cell lines: a. MDCK, b. HaCaT, c. Jurkat, and d. K562. The cloned fragments showed
differential activity in different cell lines, indicating the presence of cell type-specific enhancers. The fragment with the SNP 27:19,086,778
contained the most potent enhancer showing the highest activity in HaCaT cells (8 vs. 11-fold induction) with significant allelic difference
(p = 0.003). All except SNP 27:19,114,170 showed allelic differences in at least one cell line
Fig. 3 Summary of the workflow and major results. This study was initiated by the previous findings in [20], which thus serve as background
(purple text boxes) for the present study (light blue boxes). Red arrows indicate the next step in the workflow
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and SNP 27:19,112,169), whereas in the remaining six
regions the risk allele always conferred an increased ex-
pression compared to the control allele when a signifi-
cant allelic difference was observed.
The fragment containing SNP 27:18,861,228 showed the
strongest effect on expression in Jurkat cells (4-fold induc-
tion compared to the control vector with a minimal
promoter), but allelic difference was observed only in
MDCK cells (p = 0.008). The fragment with the SNP
27:19,086,778 contained the most potent enhancer show-
ing the highest activity in HaCaT cells (8 vs. 11-fold induc-
tion) with significant allelic difference (p = 0.003), whereas
a 4-fold induction with no allelic difference in MDCK cells
and allelic differences in Jurkat cells (p = 0.0002, 2-fold)
and K562 (p = 0.0001) was observed. The fragment with
the SNP 27:19,093,355 displayed an allelic difference
(p = 0.0001) only in K562 cells consisting of repressor
effects (<0.5-fold), whereas enhancer effects were
detected in Jurkat cells (2.5-fold) and repressor effects
in HaCaT cells (<0.5-fold) without allelic differences.
The SNP 27:19,096,199-fragment showed a repressive
effect by the risk allele compared to the control in
K562 cells (p = 0.0005, 2-fold). Similarly, the SNP
27:19,112,169-fragment displayed repressive effects by
the risk allele in K562 cells (p = 0.0003, <0.5-fold) and
Jurkat cells (p = 0.0001, <0.5-fold). The SNP
27:19,114,170-fragment displayed repressive effects in
MDCK, Jurkat, and K562 cells (<0.5-fold) without
allelic differences. The SNP 27:19,135,677-fragment
was acting as a repressor of gene transcription with
allelic differences in Jurkat cells (<0.5-fold, p = 0.0001)
and K562 cells (<0.2-fold, p = 0.0001). The SNP
27:19,140,837-fragment increased expression in K562
cells (2-fold) with an allelic difference (p = 0.0001),
and allelic differences were also observed in MDCK
cells (p = 0.004) and Jurkat cells (p = 0.007).
Discussion
Whilst the structure of the dog genome makes dogs ex-
tremely useful for the initial mapping of complex disease
genes, the presence of long regions with LD within pure-
bred dogs may eventually hamper further genetic ana-
lysis of causative variants. Due to the extensive LD, we
were unable to narrow down the CAD-associated haplo-
type in GSDs alone. Instead, we performed an across-
breed analysis with a low number of control dogs of
LRCAD breeds (Nbreeds = 5, Ndogs = 40) together with 91
CAD cases and 84 controls of GSDs and defined one
top-associated SNP 27:19,086,788 and a rare 48 kb risk
haplotype in GSDs overlapping with regions of high
regulatory potential within the PKP2 gene. The low sam-
ple numbers of the LRCAD breeds and the large sample
set of GSDs included in the analysis resulted in an asso-
ciation analysis still focused on CAD association in
GSDs, with the exception that SNPs with risk alleles not
present in the LRCAD breeds increased in significance.
Whereas SNPs with risk alleles present in the LRCAD
breeds were reduced in significance. One can argue that
the low sample numbers of the LRCAD breeds may im-
plicate that risk alleles by chance was not present in the
particular dogs included in the analysis and also that
other LRCAD breeds could possibly carry the risk alleles.
The additional genotyping of SNP: 27:19,093,355 (tag-
ging the 48 kb risk haplotype) did reveal that the risk al-
lele at this locus was rare but not unique to defined
HRCAD breeds nor was it the major segregating risk
factor in LR, GR, or WHWT. Nevertheless, the associ-
ation analysis resulted in the highly significant top SNP
27:19,086,778 and clearly distinguished the rare 48 kb
risk haplotype with an OR for CAD higher than the top
GWAS SNP in GSDs. When continuing the evaluation
of the candidate SNPs defined by the association ana-
lyses, we observed allele-specific and cell type-specific
differences of expression using reporter assays where
some regions were more active in epithelial cells while
others functioned in cells of hematopoietic origin.
Our findings presented here are in line with the “mul-
tiple enhancer variant” hypothesis stating that multiple
SNPs in LD may influence multiple enhancers for a gene
[28], each with a modest effect on gene expression in
specific cell types. The very strong increase of the re-
porter expression by the fragment with the SNP
27:19,086,778 in the skin-relevant cell lines, but not in
Jurkat and K562 representing two hematopoietic cell
types, is in agreement with the lack of prominent signals
for ENCODE enhancer-associated marks in hematopoietic
cells within the locus. Moreover, the genomic region in-
cluding the ~48 kb haplotype plus the flanking top GSD
SNP 27:19,086,778, includes two strong ENCODE enhan-
cer regions active in keratinocytes and epithelial cell lines
(Fig. 1d). Overall, we detected rather modest enhancing
and even repressive activities of the regulatory regions in
the cell lines of hematopoietic origin, which may indicate
that the locus is repressed in these cell types. Indeed, in an
mRNA sequencing study, PKP2 mRNA is barely detect-
able in dog blood [29], but the risk alleles for some of the
SNPs might release this repression and activate the ex-
pression of the target genes in immune cells as well. The
risk alleles for only two of the variants (SNP 27:19,096,199
and SNP 27:19,112,169) significantly reduce expression of
the luciferase reporter in contrast to other associated
SNPs, and this also suggest that they act independently of
the other SNPs, or even on another gene. A recent report
showed that enhancer regions in dogs may be separated
from the affected gene by several non-relevant genes and
more than 1 Mb [30]. Thus, the genes DNM1L, YARS2, or
FGD4 located close (~30-150 kb) to PKP2, may also be
regulated by enhancers harboring the candidate variants
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despite their location within PKP2. Of note, the protein
encoded by FGD4 may be relevant for CAD development
as it is expressed in hematopoietic cells, and has functions
implicated in allergen-sensitized dendritic cells [31] and in
parasite invasion through the gastro-intestinal tract [32].
A recent study in dogs showed that PKP2 mRNA ex-
pression was significantly up-regulated in atopic skin
compared to healthy skin. The difference was detected
in non-lesional skin vs. control skin (p = 0.03) and was
even more pronounced in lesional-skin vs. control skin
(p = 0.001) [33]. The position of the candidate variants
defined and evaluated in the present study were located
close to the epithelial-specific enhancer region within
the PKP2 gene. Especially the fragment containing SNP
27:19,086,778 with strong enhancer effects on gene tran-
scription supports the notion that the effect on CAD, by
this locus, originates primarily from the PKP2 gene and
its regulation by this enhancer in the skin. Furthermore,
the significantly higher expression of the fragment with
the risk allele compared to the control allele in keratino-
cytes suggests that the SNP 27:19,086,778 risk allele
contributes to an increased transcription of PKP2 in the
skin of CAD-affected GSDs.
To conclude if the expression of PKP2 and/or any
other genes in the nearby region is altered due to the
risk variants, mRNA and protein expression analyses in
tissues from relevant dogs are necessary. Relevant tissues
may include both immune cells, and skin as well as
additional epithelial tissues such as intestine epithelium
as it is known that intestine integrity and allergen uptake
is of high relevance in atopic skin manifestations [34,
35]. Skin tissue samples of lesional skin should optimally
be collected from untreated CAD-cases to avoid interfer-
ence by treatment on gene and protein expression, and
healthy skin of control GSDs should be collected from
the same body locations for comparison. Though, the
exact effect on transcription caused by each variant as
well as by the combination of variants may only be
revealed using advanced experiments of live rodent
models and gene-editing methods such as the CRISPR
Cas9 technology [36].
CAD is a complex disease where genetic risk factors at
multiple loci in combination with environmental risk
factors contribute to CAD development. In GSDs, low
serum IgA levels are highly correlated with CAD, thus
this is one important risk factor for CAD defined in this
breed [20, 37]. Also, interaction of genes within the
PKP2 locus and other genetic risk loci, including the
newly identified loci associated with IgA levels in GSDs
[38], may be of substantial importance for CAD develop-
ment in GSDs. Even within the associated region on
CFA27 (defined by GWAS) additional regulatory
variants may be contributing to the CAD predisposition
seen in GSDs. In our data set, only HRCAD breeds
carried the 48 kb risk haplotype (GSD, LR, and GR) or
part of it (WHWT). However, no association with CAD
was detected in LRs, WHWTs, and GRs for the tagging
SNP 27:19,093,355 genotyped in the extended datasets.
The high frequencies of the risk allele in LRs (80 %) and
WHWTs (55 %) may partly explain the overall increase
of CAD in the breeds but where the main segregating
risk factors are located within other breed-specific loci.
The control haplotype 5, consisting of control alleles at
the nine candidate SNP positions covering a region of
280 kb, conferred a protective effect in GSDs and was
present in almost all breeds included in the fine-
mapping. Interestingly, LR and WHWT (and Jack Rus-
sell Terriers: sample size = 1) were the only breeds in
which the control haplotype 5 was not detected. Per-
haps, this may also contribute to the lack of signal in LR
and WHWT where the majority of dogs within these
breeds carry regulatory risk variants across this locus.
Conclusions
This study demonstrates that the contribution from the
PKP2 locus to CAD development in GSDs is dependent
on several regulatory risk variants influencing cell type-
specific transcription. This highlights the complexity of
the associated locus and its effect on gene regulation,
but also the complex nature of the disease involving sys-
temic immune responses and skin damage. An altered
expression pattern of the target gene(s) in either im-
mune or epithelial cells may lead to perturbations in dif-
ferent signaling pathways, which jointly contribute to
pathological changes in CAD. It is also possible that dif-
ferent enhancers actually regulate different genes located
within this locus, and therefore we may expect even
more complex tissue-specific changes in the expression
pattern. No single causative variant could be identified,
and we conclude that part of the predisposition to CAD
in GSDs can be explained by multiple regulatory vari-
ants. These are located in tissue-specific enhancers
within the PKP2 locus that most likely jointly participate
in transcriptional regulation at this locus influencing
PKP2 mRNA expression and nearby genes.
Methods
Sampling
Blood samples were collected from privately owned dogs
in collaboration with several veterinary clinics through-
out Sweden and Switzerland. Informed owner consent
was obtained for each dog.
DNA preparation
Genomic DNA was extracted from EDTA blood samples
using the Qiagen mini- and/or midiprep extraction kit
(Qiagen, Hilden, Germany). DNA samples were diluted
in H2O and stored at −20 °C until used for genotyping.
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Phenotype classifications
Phenotype definitions of the CAD cases and controls are
described in detail in [20]. In short, CAD cases had posi-
tive reactions on allergen-specific IgE tests, after care-
fully ruling out other causes of pruritus including a
conducted diet trial to define cutaneous adverse food
reactions. CAD controls were older than five years of
age with no history of pruritus, repeated ear infections
or skin lesions compatible with CAD. Based on clinical
experience by veterinary dermatology specialist (author
Kerstin Bergvall, KB), Giant Schnauzer, Hovawart, Irish
wolfhound, Smalands hound, and Norwegian elkhound
were defined as typical LRCAD breeds. Based on previ-
ous publications Boxer, Bull terrier, WHWT, GSD, LR,
[8–11], GR [10, 12] and Soft-coated wheaten terrier, and
Wachtelhund [8] were classified as HRCAD breeds.
Selection of SNPs for genotyping
We used the targeted re-sequencing data generated
using a 385 K custom-designed sequence capture array
from Roche NimbleGen, WI, from five GSDs where in
total 9503 SNPs were identified in the entire 2.8 Mb
region on CFA27 using the canine genome version: Can-
Fam2.0 (Additional file 14: Table S14) [20]. We used the
same canine genome version (CanFam2.0) for assigning
SNP positions throughout the current study to make
comparisons to our previous study [20] feasible. The
top-associated region within the PKP2 locus covered
~209 kb (block 7–11), and due to the LD pattern (see
Figure 4 in [20]) we included an extended candidate re-
gion of ~340 kb stretching from SNP 27:18,804,142
(r2 > 0.8 with neighboring SNP in block 7) to SNP
27:19,142,893 (end of block 11). Within this region, 894
SNPs followed the same pattern as the top two GWAS
SNPs in the re-sequenced GSDs: one case homozygous
for the risk allele (T6), two heterozygous cases (T7 and
T8), and two controls homozygous for the control allele
(T1 and T2; Additional file 15: Table S15).
In total, 102 SNPs within the 340 kb candidate region
(selected SNPs are in the fourth column in Additional
file 15: Table S15) were selected based on the following
criteria: 1) 35 SNPs were selected based on the compari-
son of our set of SNPs to the SNPs identified in previ-
ously published whole genome sequence data from six
dog- and wolf pools (described in [25]). We made our
own division, based on clinical experience (KB), into dog
pools with LRCAD breeds: Pool 2 (Smalands hound,
Norwegian elkhound, Swedish elkhound, and Finnish
Lapphund), Pool 4 (Drever) and Pool 5 (Belgian
Tervueren). Pool 3 (English cocker spaniel, Springer
spaniel, GR, and LR) and Pool 6 (Bearded collie,
Hovawart, Giant schnauzer, and GSD) were considered
as HRCAD pools based on the presence of the HRCAD
breeds GR, LR, and GSD. Pool 1 (the wolf pool) was
considered as either or, as we do not know if the CAD
risk factor(s) arose before or after dog domestication.
We compared SNPs from our GSDs to the SNPs identi-
fied with the pool data within the 340 kb region, and
considered i) SNPs from the GSD data that were not
found in the pool data (thus possibly functionally im-
portant) and ii) SNPs where LRCAD were fixed for the
GSD control allele, as candidates. 2) 24 SNPs were lo-
cated in the human regulatory region of PKP2 (accord-
ing to the UCSC human browser) corresponding to dog
CFA27 ~ 19.01–19.04 Mb. 3) 36 SNPs were chosen in
order to cover the whole 340 kb candidate region. 4) For
comparison, we added the already genotyped top two
GWAS SNPs, and the top six SNPs from the previous
fine-mapping (SNP 27:19,140,837 was the top-associated
SNP in both categories).
We also included 20 SNPs outside the defined 340 kb
region by choosing eight SNPs within 18.45–18.54 Mb,
six SNPs around 19.14–19.15 Mb, and six SNPs within
19.17–19.30 Mb (Additional file 16: Table S16). These
regions showed association (yet, lower than the top re-
gion) in the previous fine-mapping (see details in [20]).
The final number of selected SNPs was 122, out of
which 120 were successfully designed into four pools for
genotyping using the iPLEX Sequenom MassARRAY
platform.
Association analyses in GSDs and other breeds
We used the GenABEL package ver. 1.8-0 [39], a part of
R statistical suite/software, ver. 0.98.932 [40] for the
quality control and association analyses. The simplest
model qtscore (fast score test for association between a
trait and genetic polymorphism) was applied. In total,
381 dogs and 120 SNPs were genotyped and 104 SNPs
remained after quality controls (Additional file 1: Table
S1) due to the exclusion of 16 SNPs with call rate < 0.1.
The sample set consisted of the same GSDs used in the
GWAS [20] (except for two GSD controls missing DNA)
and CAD cases and controls of typical HRCAD breeds
and LRCAD breeds. In total, 11 samples (three WHWTs,
two Bull terriers, one Boxer, three GSDs, one Smalands
Hound, and one Rhodesian ridgeback) were excluded
due to call rate below 60 %. The 370 samples remaining
for the analyses were 329 dogs of HRCAD breeds and
41 control dogs of LRCAD breeds (Table 1). Association
analyses were performed in GSDs only and in GSDs
combined with the CAD controls of LRCAD breeds (the
mixed breed excluded). While the fine-mapped region
was defined as genome-wide significant based on permu-
tations in [20], we set out to select the top-associated
SNPs within the region which would potentially have the
strongest impact on gene regulation and thus with most
effect on the phenotype.”
Tengvall et al. BMC Genetics  (2016) 17:97 Page 11 of 14
Selection of candidate SNPs within the 48 kb associated
haplotype
We used the targeted re-sequencing data from five
GSDs [20] to systematically go through an extended
version of the 48 kb associated haplotype that
spanned ~52 kb from SNP 27:19,088,686 to SNP
27:19,140,837 (including the regions to the next geno-
typed SNP). From 114 SNPs called in this region, we
selected candidates that were in LD with the top two
GWAS SNPs in the GSDs re-sequence data, and with
risk alleles not present in previously published whole
genome sequence data from LRCAD breed pools [25],
human, or other species (see Methods). We also ex-
cluded SNPs in repeat elements and those not
mapped in the human genome. Using these criteria,
nine candidate SNPs were selected, out of which six
were included in the fine-map genotyping of 120 SNPs and
five were among the 104 SNPs remaining after quality con-
trols (Additional file 6: Table S6). The mutated and the
wild-type sequences of the nine candidates were screened
for transcription factor binding site predictions by the web-
tool TRAP [26, 27] (http://trap.molgen.mpg.de/cgi-bin/
trap_two_seq_form.cgi).
Additional genotyping of SNP 27:19,093,355
Additional genotyping of SNP 27:19,093,355 was per-
formed using TaqMan® (Lifetechnologies) protocol for
allelic discrimination. We genotyped a few samples from
a large number of breeds (Ndogs = 346, Nbreeds = 43) and
also a larger sample set of GR, LR, and WHWT, and
GSD, obtained from other projects and collaborators
(Additional file 8: Table S8).
Odds ratio calculations
The ORs were calculated according to the following
formula:
OR ¼ DE=HE
DNE=HNE
where DE is the set of cases with the mutation (homozy-
gous or heterozygous), HE is the set of controls with the
mutation, DNE is the set of cases without the mutation
(homozygous for the control allele), and HNE is the set
of controls without the mutation.
Haplotype analysis
We selected the top SNPs from both analyses: SNP
27:19,086,778, and top second: SNP 27:19,140,837 and
third: SNP 27:19,124,996 from the GSD association
analysis as well as the top second GWAS SNP
27:18,861,228 [20]. Within the 48 kb risk haplotype
(from the association of GSD and LRCAD breeds), we
selected the four most associated SNPs: 27:19,135,677,
27:19,112,169, 27:19,114,170, 27:19,096,199, and the
sixth most associated SNP 27:19,093,355 (based on the
TF predictions). In total, nine SNPs were selected for
further evaluation. We used PHASE 2.1.1 to define the
nine-SNP haplotypes across all breeds and used Fisher’s
Exact probability test (two-tailed) to examine the associ-
ation of the haplotypes in GSDs.
Luciferase reporter assays
The luciferase reporter assay was used to examine the
regulatory potential of each of the following SNPs inde-
pendently: SNP 27:18,861,228, SNP 27:19,086,778, SNP
27:19,093,355, SNP 27:19,096,199, SNP 27:19,112,169,
SNP 27:19,114,170, SNP 27:19,135,677, and SNP
27:19,140,837. The corresponding dog genomic DNA
fragments, harboring the SNPs, were PCR amplified and
cloned in front of the minimal promoter in the pGL4.26
luciferase reporter vector (Promega). The sizes of the
SNP-containing fragments used to construct the
reporters for luciferase assays were as follows: SNP
27:18861228, 318 bp; SNP 27:19086778, 517 bp; SNP
27:19093355, 479 bp; SNP 27:19096199, 324 bp; SNP
27:19112169, 211 bp; SNP 27:19114170, 266 bp; SNP
27:19135677, 164 bp; SNP 27:19140837, 406 bp. The se-
quences of the fragments used are shown and the associ-
ated SNPs located in each fragment are indicated in bold
red and additional SNPs in red (Additional file 13: Table
S13). The plasmids were validated by sequencing and
purified with EndoFree Plasmid Maxi Kit (Qiagen) for
transfection into Madin Darby Canine Kidney epithelial
cell line from Cocker spaniel (MDCK), human immor-
talized keratinocyte cell line (HaCaT), human T cell line
(Jurkat), and human erythromyeloblastoid leukemia cell
line (K562). All transfections were performed in the 24-
well plates as follows: for Jurkat and K562: 7 × 105 cells/
well were seeded in the RPMI-1640 medium supple-
mented with GlutaMAX and 10 % of heat-inactivated
bovine serum just before the transfection; for MDCK
and HaCaT: 3x105 cells/well were seeded in the DMEM
medium with GlutaMAX and serum 24 h prior to trans-
fection. Lipofectamine 2000 (Invitrogen) was used in ac-
cordance with the manufacturer’s protocol to deliver
DNA including 750 ng of the reporter plasmid and
50 ng of the pRL-TK (Promega) vector to cells in each
well. Forty-eight hours after transfection, the cells were
harvested and assayed for the Firefly and Renilla lucifer-
ase activities with the Dual-Luciferase Reporter Assay
System (Promega). The luciferase activity provided by
the control vector was set to 1, and then the test
reporters’ activities as fold-change compared to the con-
trol. The experiment was repeated three times with four
technical replicates for each plasmid and analyzed with a
t-test.
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